持续走向全国，走入消费者心智，公司成功启动"为爱常备，救在身 边，达仁堂速效救心公益行动"。达仁堂大国品牌项目登陆央视；圆 满承办第十一届中药材基地共建共享交流大会； "中医药文化守护官" 证券代码：600329 证券简称：达仁堂 编号：临 2025-033 号 津药达仁堂集团股份有限公司 关于 2024 年度"提质增效重回报"行动方案的评估 报告暨 2025 年度"提质增效重回报"行动方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为推动公司高质量发展，更好回报投资者，津药达仁堂集团股份 有限公司（以下简称"公司"）深入贯彻落实国务院《关于进一步提 高上市公司质量的意见》，积极响应上海证券交易所《关于开展沪市 ，制定 2024 年度"提质增效 公司"提质增效重回报"专项行动倡议》 重回报"行动方案，公司持续聚焦主业，提升新质生产力，规范治理， 回报股东，加强投资者沟通工作。现将公司 2024 年度"提质增效重 回报"行动方案落实情况暨 2025 年度"提质增效重回报"行动方案 报告如下： 一、聚焦核心工业，聚力核心 ...

近日，手握"速效救心丸"的百年药企达仁堂交出一份撕裂的半年报：净利润同比暴涨193%至19.28亿 元，营收却暴跌33.15%至26.51亿元。这已是其营收连续第三年下滑，2023年、2024年分别下降0.33%、 11.14%。 亮眼利润背后，是两笔关键资产出售的支撑。2025年上半年，达仁堂先后出售中美天津史克制药有限公 司12%股权，实现税后净收益13.08亿元。正是这笔巨额收益，将净利润推上19亿元高位。若剔除该因 素，其扣非净利润仅为5.96亿元，同比下滑5.99%。 达仁堂前任董事长张铭芮曾将退出天津史克归因于"40年合作期满、战略调整、资金回笼投入新业务"。 但当下的财报显示，13亿股权收益如同速效救心丸——能短暂刺激心跳，却难根治机体沉疴。百年老字 号若想真正"救心"，仍需回归产品创新与合规经营的本源。当资本运作的喧嚣退去，市场终将检验其主 业的成色。 本文结合AI工具生成 责任编辑：AI观察员 质量合规问题频发埋下隐患。2022年人参健脾丸因劣药问题被罚；2024年京万红药业遭FDA通报GMP 缺陷；旗下药房因医保违规被约谈。2025年以来，12315平台相关投诉超20条，涉及质量、宣传、售 ...

Core Viewpoint - Hainan Huhuwawa Pharmaceutical Group Co., Ltd. faces significant internal control issues, leading to a negative audit opinion and a stock trading suspension, with a change in stock abbreviation to "ST Huhuwawa" starting April 30, 2025 [1][3][5] Financial Performance - For the fiscal year 2024, the company reported a revenue of 1.414 billion yuan, a year-on-year decrease of 21.26%, and a net profit attributable to shareholders of -274 million yuan, a staggering decline of 2629.23% [10] - In the first quarter of 2025, the company achieved a revenue of 337 million yuan, down 28.42% year-on-year, with a net profit of approximately 24.35 million yuan, a decrease of 11.23% [10] Internal Control Issues - The audit report from Lixin Certified Public Accountants highlighted three major areas of concern regarding internal controls, including the lack of complete financial data related to restated financial statements and issues with accounts receivable from key clients [3][5] - The company has been criticized for significant deficiencies in its internal control over financial reporting, resulting in a negative opinion from the auditors [5] Management Changes - The company's general manager, Zhang Mingrui, resigned for personal reasons less than two months after taking office, marking a period of instability in leadership [2][6] - This resignation follows the earlier departure of Liu Jingping from the general manager position, who remains as chairman and has been a key figure in the company since its inception [7][8] Related Transactions - In 2024, the company purchased eight R&D projects from Hainan Zhongwang Medical Technology Development Co., Ltd. for 42.0537 million yuan, raising concerns due to familial ties between the company's actual controller and the legal representative of the vendor [4]